1    **Supplementary table 1.** Relationship between IGF-I hormonal response to pasireotide

2    treatment and T2- weighted MRI signal.

| | Total evaluable cases[a] | IGF-I Hormonal Response | Hypointense T2-weighted MRI signal | Iso/Hyperintense T2-weighted MRI signal | p |
|---|---|---|---|---|---|
| % IGF-1 reduction over ULN  at 6 months | 58[a] | 36±3 | 34±6 | 37±3 | 0.44 |
| Complete normalization of IGF-I at 6 months | 58 | 30 (52%) | 9/19 (47%) | 21/39 (54%) | 0.59 |
| % IGF-1 reduction over ULN at 12 months | 50 | 36±6 | 20±18 | 42±5 | 0.59 |
| Complete normalization of IGF-I at 12 months | 50 | 29 (58%) | 7/13 (54%) | 22/37 (60%) | 0.78 |

3

4    Data are shown as mean ± standard error or number (percentage).

5    [a] Having excluded patients who received radiotherapy more than 1 year but less than

6    10 years ago.

7

8 **Supplementary table 2.** Relationship between tumor response to pasireotide

9 treatment and T2- weighted MRI signal.

| | Total evaluable cases[a] | Volume reduction | Hypointense T2-weighted MRI signal | Iso/Hyperintense T2-weighted MRI signal | p |
|---|---|---|---|---|---|
| Tumor shrinkage (≥25%) at 6 months | 42 | 19/42 (45%) | 4/13 (31%) | 15/29 (52%) | 0.32 |
| Tumor shrinkage (≥25%) at 12 months | 37 | 17/37 (46%) | 2/9 (22%) | 15/28 (54%) | 0.14 |
| Absolute tumor shrinkage ($mm^3$) at 6 months | 42 | 2262±1089 | 760±762 | 2936±1533 | 0.01 |
| Absolute tumor shrinkage ($mm^3$) at 12 months | 37 | 2356±1355 | 193±184 | 3175±1763 | 0.03 |
| % tumor shrinkage over basal residual volume at 6 months | 42 | 26±6 | 20±12 | 28±6 | 0.06 |
| % tumor shrinkage over basal residual volume at 12 months | 37 | 27±6 | 13±15 | 31±5 | 0.14 |

10

11 Data are shown as mean ± standard error or number (percentage).

12 [a] Having excluded patients who received radiotherapy more than 1 year but less than
13 10 years ago.